Focusing gene-level interrogation on the lung cancer model (A549) allowed us to (i) align molecular readouts with the drug’s clinical indication, (ii) concentrate on EGFR-axis and cytoskeletal pathways central to our priori hypothesis, and (iii) limit multiple comparisons that inflate false-positive rates when profiling across divergent disease contexts. This evidence concerns the gene EGFR and lung carcinoma.